BusinessSummit Presents New 24-Week Analyses from PhaseOut DMD at the 2018 American Academy of Neurology Annual MeetingBy Nasdaq OMXApr 20, 2018, 11:00 AM UTC
BusinessSummit Completes Dosing of Ezutromid in PhaseOut DMD Clinical TrialBy Nasdaq OMXApr 19, 2018, 11:01 AM UTC
BusinessSummit Therapeutics Announces Placement of £15.0 Million of Ordinary SharesBy Nasdaq OMXMar 27, 2018, 11:01 AM UTC
BusinessSummit Highlights Scientific Rigour of its PhaseOut DMD Clinical Trial at MDA Clinical ConferenceBy Nasdaq OMXMar 14, 2018, 11:00 AM UTC
BusinessSummit Expands Enrolment in PhaseOut DMD Phase 2 Clinical Trial to Include Planned Additional GroupBy Nasdaq OMXMar 7, 2018, 12:02 PM UTC
BusinessSummit Announces New Analysis Showing Ezutromid Significantly Reduced Muscle Inflammation in Phase 2 Clinical Trial in DMDBy Nasdaq OMXFeb 26, 2018, 12:00 PM UTC
BusinessEzutromid Significantly Reduced Muscle Damage in DMD Patients in 24-Week Interim Data From Summit’s PhaseOut DMD Clinical TrialBy Nasdaq OMXJan 25, 2018, 12:01 PM UTC
BusinessSanthera Pharmaceuticals, Summit Therapeutics, Catabasis Pharmaceuticals and Duchenne UK to host Duchenne Muscular Dystrophy Awareness DayBy Nasdaq OMXDec 6, 2017, 7:00 AM UTC
